Trial Profile
A Phase I dose escalation trial of combination of GRANITE-001 with systemic Opdivo and Yervoy
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 24 Jul 2018
Price :
$35
*
At a glance
- Drugs GRANITE 001 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 24 Jul 2018 New trial record
- 19 Jul 2018 This trial is expected to start before the end of 2018 and is being conducted under a collaboration agreement between Bristol-Myers Squibb Company and Gritstone Oncology, according to a Gritstone Oncology media release.